

## Cardiovascular Disorders

### 1-Acute rheumatic fever

1-Acute rheumatic fever remains an important preventable cause of cardiac disease <sup>(1)</sup>. Acute rheumatic fever **usually affects children** (most commonly between 5 and 15 years) or young adults <sup>(2)</sup>.

2-The condition is triggered by **an immune-mediated response to infection with specific strains of group A streptococci**, which have antigens that may cross-react with cardiac myosin and membrane protein. Antibodies produced against the streptococcal antigens cause inflammation in **the heart as well as the joints and skin** <sup>(2)</sup>.

**Table 1: criteria for the diagnosis of rheumatic fever**

Major manifestations	
• Carditis	• Erythema marginatum
• Polyarthriti	• Subcutaneous nodules
• Chorea	
Minor manifestations	
• Fever	• Raised ESR or CRP
• Arthralgia	• Leucocytosis
• Previous rheumatic fever	• First-degree AV block
Plus	
• Supporting evidence of preceding streptococcal infection: recent scarlet fever, raised antistreptolysin O or other streptococcal antibody titre, positive throat culture	

<sup>(2)</sup>.

### Clinical features

1-Acute rheumatic fever is a multisystem disorder that usually presents with **fever**, and **joint pain**, **2–6 weeks after an episode of streptococcal pharyngitis** <sup>(1, 2)</sup>.

2-The presence of either two **major criteria** or one major and two **minor criteria**, along with evidence of preceding **streptococcal infection**, confirm a diagnosis of acute rheumatic fever.

[Streptococcal antibody tests, such as the antistreptolysin O (**ASO**) titer, are the most reliable laboratory evidence of prior infection].

### Management of the acute attack

1-A single dose of benzyl penicillin 1.2 million U i.m. or oral phenoxymethyl penicillin for 10 days should be given on diagnosis to

eliminate any residual streptococcal infection. If the patient is penicillin-allergic, erythromycin or a cephalosporin can be used.

**2-Bed rest is important**, as it lessens joint pain and reduces cardiac workload.

**3-Aspirin:** This will usually relieve the symptoms of arthritis rapidly. The usual dose of aspirin is 100 mg/kg/24 hr divided qid PO for 3-5 days, followed by 75 mg/kg/24 hr divided qid PO for 4 wk.

4-Patients with carditis and cardiomegaly or congestive heart failure should receive **corticosteroids**.

The usual dose of prednisone is 2 mg/kg/24 hr in 4 divided doses for 2-3 wk followed by a tapering of the dose that reduces the dose by 5 mg/24 hr every 2-3 days.

5-Supportive therapies for patients with moderate-to-severe carditis include **digoxin, fluid and salt restriction, diuretics, and oxygen**.

## 2-Viral Hepatitis

### Etiology

1-There are six primary hepatitis viruses: Hepatitis A virus (HAV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Hepatitis D virus (HDV), Hepatitis E virus (HEV) and Hepatitis G virus (HGV).

2-They differ in their transmission, severity, likelihood of persistence, and subsequent risk of hepatocellular carcinoma.

	<b>HAV</b>	<b>HBV</b>	<b>HCV</b>	<b>HDV</b>	<b>HEV</b>	<b>HGV</b>
<b>Transmission</b>	Fecal-oral	Transfusion, sexual, perinatal	Parenteral, transfusion, perinatal	Similar to HBV	Fecal-oral	Parenteral transfusion

**Note** - The most important risk factor for acquisition of **HBV in children is perinatal exposure to infected mother**. In most cases, transmission **occurred at the time of delivery**; virus contained in amniotic fluid or in maternal blood may be the source. However less commonly intrauterine infection occurred .

**3-HBV and HCV cause chronic infection**, which may lead to **cirrhosis** and is a significant risk factor for **hepatocellular carcinoma** .

## Clinical Manifestations

1-**Asymptomatic or mild**, nonspecific illness without icterus (jaundice) is **common** with HAV, HBV, and HCV, **especially in young children**.

2-The **preicteric phase**, which lasts approximately 1 week, is characterized by headache, anorexia, malaise, abdominal discomfort, nausea, and vomiting and usually precedes the onset of clinically detectable disease.

3-**Jaundice** and tender **hepatomegaly** are the most common physical findings and are characteristic of the **icteric phase**. Hepatic enzymes may increase 15- to 20-fold.

4-Resolution of the hyperbilirubinemia and normalization of the transaminases may take 6 to 8 weeks .

## Complications

1-Most cases of acute viral hepatitis resolve without specific therapy, with less than 0.1% of cases progressing to **fulminant hepatic necrosis** which is associated with a high mortality rate.

2-**HAV and HEV cause acute infection only**. HBV, HCV, and HDV may persist as **chronic infection** with chronic inflammation, fibrosis, and **cirrhosis and the associated risk of hepatocellular carcinoma** .

## Diagnosis

The diagnosis of viral hepatitis is confirmed by **serologic testing**.

## Treatment

1-The treatment of acute hepatitis (**except HCV** ) is largely supportive and involves rest, hydration, and adequate nutrition. Hospitalization is indicated for severe cases .

2-**Chronic HBV** infection may be treated with **interferon alfa-2b or lamivudine**, and HCV may be treated with interferon alfa usually in combination with Ribavirin .

## Respiratory Disorders

### 1-Cystic Fibrosis

#### Background

1-Cystic fibrosis (CF) is an autosomal recessive multisystem disorder caused by mutations in the *cystic fibrosis transmembrane regulator (CFTR)* gene.

2- CFTR is important for the proper movement of salt and water across epithelial cell membranes especially in the airways, liver, and pancreas . The term *cystic fibrosis* arises from the fibrotic scar tissue that replaces the destroyed pancreas .

## Pathophysiology

### A-Pulmonary System

1-In CF, there are reduced chloride secretion with excessive sodium resorption which lead to dehydration of the airway lining leading to airway obstruction. This, in turn, leads to colonization with bacteria especially *Staphylococcus aureus* and *Pseudomonas aeruginosa* .

2-Chronic lung disease is a hallmark of CF, leading to death in 90% of patients . CF patients will usually experience **chronic respiratory infections** .

### B-Gastrointestinal Involvement

1- Approximately 10% of patients with CF are born with intestinal obstruction caused by inspissated meconium (**meconium ileus**). In older patients, intestinal obstruction may result from thick inspissated mucus in the intestinal lumen .

### C-Hepatic Involvement

1-In patients with CF, there is reduction in water and sodium movement into the bile. **The resulting decrease in the volume and flow of bile leads to stasis and obstruction of the biliary tree.** With chronic obstruction, this leads to **biliary cirrhosis** .

### D-Pancreatic Involvement

1-The obstruction of the pancreatic ducts result in the inability to excrete pancreatic enzymes into the intestine. This leads to malabsorption of proteins, sugars (to a lesser extent), and **especially fat**. Fat malabsorption manifests clinically as **steatorrhea** (large foul-smelling stools), **deficiencies of fat-soluble vitamins** (A, D, E, and K), and **failure to thrive**.

### E-Sweat Gland

In the sweat duct, CFTR reabsorbs chloride from sweat. Dysfunctional CFTR results in a **nearly fivefold elevation in sweat chloride concentrations**. This is the principal laboratory criterion for diagnosis of CF ( **sweat chloride test**) .

## Diagnosis

CF is most commonly diagnosed on the basis of typical **signs and symptoms** and an abnormal sweat chloride concentration (>60 mEq/L) ( **sweat chloride test**).

## Treatment

The treatment of CF is multifactorial, but it is primarily directed toward the gastrointestinal and pulmonary complications.

### A-Gastrointestinal System

1-**Pancreatic enzyme replacement** (lipase, protease, and amylase) is the mainstay of gastrointestinal therapy .

2-**Fat-soluble vitamins (A, D, E, and K) supplementation** is usually required in

pancreatic insufficiency.

3-The use of **ursodeoxycholic acid (UDCA)** may improve bile flow, prevent obstruction and slow progression of liver disease .

## **B-Treatment of Cystic Fibrosis Airway Disease**

Treatment of CF airway disease involves the use of medications and techniques to mobilize pulmonary secretions, and antibiotics to manage infection .

### **1-Mucociliary Clearance**

**A-Physical Therapy:** Airway clearance can be performed using various techniques. These techniques are recommended **on a daily basis to help mobilize secretions** .

**B-Mucolytic Therapy:** Sputum viscosity is increased by the large quantities of extracellular DNA that result from chronic airway inflammation and degradation of neutrophils. **Inhaled recombinant human deoxyribonuclease** (rhDNase, dornase alpha) cleaves extracellular DNA in sputum.

**C-Airway Hydration Therapies :** Inhalation of hypertonic saline rehydrates the airways through osmotic flow of water.

**D-Bronchodilators:**  $\beta$ -Agonists keep airways open and facilitate airway clearance

### **2-Antibiotics**

1-Antibiotics are used to treat lung infection. *Typical regimens for severe infections include an antipseudomonal  $\beta$ -lactam plus an aminoglycoside for added synergy and delay of resistance development*

2-**Fluoroquinolone** use is common among CF patients infected with *P. aeruginosa*, even in children.

3-**Chronic maintenance antibiotic therapy may be used in patients with Pseudomonas colonization** in an attempt to prevent bacterial overgrowth. **Inhaled tobramycin** has been studied the most extensively

## **Pharmacokinetic Considerations**

CF patients have **larger volumes of distribution of many antibiotics** and also have an enhanced total body clearance. As a result of these pharmacokinetic changes, **higher doses of antibiotics** (e.g. aminoglycosides, and  $\beta$ -lactam antibiotics) are needed

## **Lung transplantation**

**Lung transplantation** is currently the only definitive treatment for advanced cystic fibrosis

### **Prognosis**

The longevity of patients with cystic fibrosis is increasing, and the median survival age is over 35 years. Death occurs mostly from pulmonary complications

### **Endocrinology**

#### **1-Diabetic ketoacidosis (DKA)**

**1-Definition:** Arterial pH <7.30, bicarbonate <15 meq/L, glucose >250 mg/dL, and Urinary ketones

2-DKA is a major **medical emergency** and remains a serious cause of morbidity, principally in people **with type 1 diabetes (More common in type 1 DM but can occur in type 2 DM)**

3-A significant number of **newly diagnosed diabetic children** present with DKA. In children with known diabetes, DKA occurs in patient who omit insulin doses or who do not successfully manage an intercurrent illness

### **Risk Factors**

1-**Omission of insulin** is the most common precipitant of DKA

2-**Infections**, acute medical illnesses, and stress of recent surgical procedures can contribute to the development of DKA

### **Pathophysiology**

1-The **hyperglycaemia** causes a profound **osmotic diuresis** leading to **dehydration**, hyperosmolarity, and **electrolyte loss**, particularly of sodium and potassium

2-Owing to increased lipolysis and decreased lipogenesis, free fatty acids are converted to ketone bodies and lead to **metabolic acidosis**

3- **Electrolyte abnormalities** occur through a loss of electrolytes in the urine In addition, The resulting metabolic acidosis causes efflux of potassium from cells, results in intracellular potassium depletion

### **Clinical Presentation**

1-Patients with DKA present initially with **polyuria, polydipsia, nausea, and vomiting. Abdominal pain** occurs frequently

2-Respiratory compensation for acidosis results in **tachypnea with deep**

**(Küssmaul) respirations.** The **fruity odor of acetone** frequently can be detected on the patient's breath

3-An altered mental status can occur, ranging from disorientation to coma

### **Management**

1-DKA is a **medical emergency** which should be treated in hospital. The principal components of treatment are :

- The administration of **short-acting** (soluble) insulin
- **Fluid** replacement
- **Potassium** replacement
- The administration of **antibiotics** if infection is present

Note: for more detailed about for the management of ketoacidosis , there is a **Diabetic Ketoacidosis Treatment Protocol**

### **Complications**

The most concerning complication of DKA is **cerebral oedema** (Treatment by Mannitol 1 g/kg IV)